R. Burnside

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

D. Cooper, A. Lazzarin, M. Saag, 2014, AIDS.

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

M. Saag, I. Frank, R. Wood, 2010, HIV clinical trials.

The Influence of Different Relapse Criteria on the Assessment of Long‐Term Efficacy of Sertraline

S. Montgomery, R. Burnside, D. Doogan, 1991, International clinical psychopharmacology.

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

M. Nelson, R. Gulick, J. Heera, 2014, Journal of acquired immune deficiency syndromes.

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program

M. Battegay, A. Lazzarin, H. Valdez, 2010, Journal of the International AIDS Society.